Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

14

Revenue 2014

Lilly

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.

Novo's semaglutide beats Lilly's Trulicity in diabetes contest

Novo's semaglutide beats Lilly's Trulicity in diabetes contest

Novo's semaglutide beats Lilly's Trulicity in diabetes contest. Analysts predict the drug could be worth $8.7bn in the next five years. ... Novo Nordisk says its once-weekly GLP-1 agonist semaglutide could become a "new standard" in type 2 diabetes after

Type 2 diabetes market set to soar, says GlobalData

Type 2 diabetes market set to soar, says GlobalData Eli Lilly is proving stiff competition for the Danish drug maker though after a stellar performance from its diabetes drug Trulicity (dulaglutide) climbing 160% to $373m in the first three months

Baricitinib delay casts a pall over Lilly's results update

Baricitinib delay casts a pall over Lilly's results update Baricitinib delay casts a pall over Lilly's results update. FDA requests further data that could keep the drug off the market for a couple of years. ... Eli Lilly is facing a lengthy delay in the US approval of its would-be arthritis blockbuster

Lilly pays Nektar $150m upfront for phase I autoimmune disease drug

Lilly pays Nektar $150m upfront for phase I autoimmune disease drug Will add another $250m if candidate meets development objectives. Eli Lilly has agreed a bolt-on deal with Nektar Therapeutics, adding an interleukin-2 (IL-2) stimulating drug called NKTR-358 - ... Under the terms of the deal, Nektar will be wholly

Race to CGRP migraine drug finish line enters the final straight

Race to CGRP migraine drug finish line enters the final straight May 17 next year, keeping them ahead of rivals Eli Lilly, Teva and Alder Biopharma. ... The start of the FDA review keeps Amgen and Novartis just ahead of fast-follower Lilly, which said in May it intends to file for its drug later this year.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Lilly
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
CNS revenue 2014
1: Pfizer
2: Biogen Idec
3: Novartis
4: Otsuka
5: Teva
6: Johnson & Johnson
7: Lilly
8: Merck KGaA
9: AstraZeneca
10: Shire
11: Bristol-Myers Squibb
12: UCB
13: Lundbeck
14: Eisai
15: GlaxoSmithKline
16: Sanofi
17: Mylan
18: Indivior
19: Actavis
20: Bayer
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Metabolic revenue 2014
1: Novo Nordisk
2: Sanofi
3: Merck & Co.
4: Lilly
5: AstraZeneca
6: Takeda
7: Novartis
8: Amgen
9: Bayer
10: Merck KGaA
11: Salix Pharmaceuticals
12: AbbVie
13: Dainippon Sumitomo Pharma
14: Kyowa Hakko Kirin
15: Mitsubishi Tanabe
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Creative effectiveness: how to achieve tangible results
Chris Field, Director and Head of Creative Services at Blue Latitude Health, reveals what it takes to create winning creative campaigns that achieve results in the Pharma market....
Patient Support Blog Series: Step two to a successful patient support programme
Break down those silos and work across internal and external stakeholders!...
Unfolding the story as two great brands unite for the good of patients
A case study by Create Health...

Infographics